AVA-METFORMIN 500 MG
METFORMIN HYDROCHLORIDE : 500 MG · DIN 02364506 · AVANSTRA INC
Health Canada status: CANCELLED POST MARKET
What is AVA-METFORMIN?
AVA-METFORMIN 500 MG contains METFORMIN HYDROCHLORIDE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02364506, held by AVANSTRA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 21-Aug-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AVA-METFORMIN used for?
Control of hyperglycemia in stable, mild, non-ketosis prone, maturity onset type of diabetes (Type II) which cannot be controlled by diet, exercise and weight reduction.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02364506 |
|---|---|
| Brand name | AVA-METFORMIN |
| Generic / active ingredient | METFORMIN HYDROCHLORIDE : 500 MG |
| Manufacturer | AVANSTRA INC |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BA02 METFORMIN |
| AHFS class | 68:20.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 21-Aug-2014 |
| Original market date | 2011-09-15 00:00:00 |
How is it administered?
Administer with meals. Dosage must be individualized based on effectiveness and tolerance. Titrate gradually to reduce gastrointestinal side effects.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (refer to Storage and Stability section 16, which is listed in TOC but text is cut off).
How is it supplied?
Not explicitly detailed in provided text (Summary section mentions 500 mg and 850 mg strengths).
Contraindications
Type I diabetes; metabolic acidosis; history of lactic acidosis; renal impairment (creatinine >136 μmol/L males, >124 μmol/L females); CHF; excessive alcohol; hepatic dysfunction; pregnancy/breastfeeding.
Warnings and precautions
Serious Warning: Lactic acidosis is a rare, fatal metabolic complication. Avoid excessive alcohol. Discontinue for radiologic studies with iodinated contrast or surgery.
What can be used instead?
Other Canadian products sharing ATC code A10BA02 METFORMIN. 45 of 122 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-METFORMIN | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02494418 |
| AG-METFORMIN | 850 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02494442 |
| APO-METFORMIN ER | 1000 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02460653 |
| APO-METFORMIN ER | 500 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02305062 |
| AURO-METFORMIN | 850 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02438283 |
| GLUCOPHAGE | 500 MG | TABLET | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02099233 |
| GLUMETZA | 1000 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02300451 |
| GLUMETZA | 500 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02268493 |
| JAMP METFORMIN | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380196 |
| JAMP METFORMIN | 850 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380218 |
Who else supplies METFORMIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METFORMIN appears in 1377 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.